Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:03:14.573Z.
Calculation as of: 2026-10-06T17:03:14.573Z.
Quote observation: 2026-10-06T17:00:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 619c5482a9d59cec4bb20d2c4447c35828cdfaa1e6076b938dd954a9c5cde0ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$1.98B
PS Ratio
2.20
TTM Avg
2.24
3Y Avg
5.62
5Y Avg
12.14
Market Cap
$1.91B
PS Ratio
7.77
TTM Avg
9.87
3Y Avg
7.83
5Y Avg
9.08
Market Cap
$1.90B
PS Ratio
19.27
TTM Avg
33.19
3Y Avg
53.74
5Y Avg
141.57
Market Cap
$2.04B
PS Ratio
2.17
TTM Avg
2.54
3Y Avg
3.32
5Y Avg
6.85
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.97B | N/A | N/A | N/A | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.96B | 7.80 | 7.66 | 4.50 | 3.89 |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 2.20 | 2.24 | 5.62 | 12.14 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 6.47 | 7.36 | 6.09 | 11.56 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | 7.77 | 9.87 | 7.83 | 9.08 |
| Immunome, Inc. (IMNM)vs › | $1.89B | N/A | 284.94 | 122.88 | 115.64 |
| Progyny, Inc. (PGNY)vs › | $2.04B | 1.55 | 1.62 | 2.06 | 3.85 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | 19.27 | 33.19 | 53.74 | 141.57 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | 2.17 | 2.54 | 3.32 | 6.85 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 18.35 | 14.63 | 12.05 | 10.52 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
